Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases

  • J Med Chem. 2019 Sep 26;62(18):8544-8556. doi: 10.1021/acs.jmedchem.9b00911.
Alen Krajnc  1 ,  Jürgen Brem  1 ,  Philip Hinchliffe  2 ,  Karina Calvopiña  1 ,  Tharindi D Panduwawala  1 ,  Pauline A Lang  1 ,  Jos J A G Kamps  1 ,  Jonathan M Tyrrell  3 ,  Emma Widlake  3 ,  Benjamin G Saward  1 ,  Timothy R Walsh  3 ,  James Spencer  2 ,  Christopher J Schofield  1
Affiliations
  • 1. Chemistry Research Laboratory, Department of Chemistry , University of Oxford , 12 Mansfield Road , Oxford OX1 3TA , United Kingdom.
  • 2. School of Cellular and Molecular Medicine, Biomedical Sciences Building, University Walk , University of Bristol , Bristol BS8 1TD , United Kingdom.
  • 3. Department of Medical Microbiology & Infectious Disease , Institute of Infection & Immunity , UHW Main Building, Heath Park , Cardiff CF14 4XN , United Kingdom.
PMID: 31454231 DOI: 10.1021/acs.jmedchem.9b00911
Abstract

The bicyclic boronate VNRX-5133 (taniborbactam) is a new type of β-lactamase inhibitor in clinical development. We report that VNRX-5133 inhibits serine-β-lactamases (SBLs) and some clinically important metallo-β-lactamases (MBLs), including NDM-1 and VIM-1/2. VNRX-5133 activity against IMP-1 and tested B2/B3 MBLs was lower/not observed. Crystallography reveals how VNRX-5133 binds to the class D SBL OXA-10 and MBL NDM-1. The crystallographic results highlight the ability of bicyclic boronates to inhibit SBLs and MBLs via binding of a tetrahedral (sp3) boron species. The structures imply conserved binding of the bicyclic core with SBLs/MBLs. With NDM-1, by crystallography, we observed an unanticipated VNRX-5133 binding mode involving cyclization of its acylamino oxygen onto the boron of the bicyclic core. Different side-chain binding modes for bicyclic boronates for SBLs and MBLs imply scope for side-chain optimization. The results further support the "high-energy-intermediate" analogue approach for broad-spectrum β-lactamase inhibitor development and highlight the ability of boron inhibitors to interchange between different hybridization states/binding modes.

Products